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Summary 
The mammalian genome contains several hundreds microRNAs that regulate gene 
expression through modulation of target mRNAs. Here, we report a fragile 
chromosomal region lost in specific hematopoietic malignancies. This 7-Mb region 
encodes about 12% of all genomic microRNAs, including miR-203. This microRNA is 
additionally hypermethylated in several hematopoieic tumors, including chronic 
myelogenous leukemias and some acute lymphoblastic leukemias. A putative miR-203 
target, ABL1, is activated in these hematopoietic malignancies in some cases as a BCR-
ABL1 fusion protein (Philadelphia chromosome). Re-expression of miR-203 reduces 
ABL1 and BCR-ABL1 fusion protein levels and inhibits tumor cell proliferation in an 
ABL1-dependent manner. Thus, miR-203 functions as a tumor suppressor and re-
expression of this microRNA might have therapeutic benefits in specific hematopoietic 
malignancies. 
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Significance 
 
We describe here a tumor suppressor microRNA, miR-203, inactivated in human 
tumors by both genetic and epigenetic mechanisms. This microRNA controls the 
expression levels of ABL1, a classic oncogene extensively characterized in 
hematopoietic malignancies. Interestingly, miR-203 also controls the expression levels 
of the BCR-ABL1 translocation protein produced by the Philadelphia chromosome, a 
hallmark of chronic myelogenous leukemia (CML). Re-expression of this microRNA 
dramatically reduces the proliferation of tumor cells in an ABL1-dependent manner. 
These results show for the first time that microRNAs are able to modulate the 
expression of tumor-specific translocation proteins. In addition, these data suggest new 
complementary therapeutic opportunities in Philadelphia+ malignancies (such as 
CMLs) and ABL1-overexpressing tumors including some acute lymphoblastic 
lymphomas or leukemias. 
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Introduction 
MicroRNAs (miRNAs) are non-coding RNAs 18-25 nt in length that regulate a variety 
of biological processes by silencing specific target genes (Ambros, 2004). miRNAs are 
well-conserved during evolution and it has been estimated that about 250-600 miRNAs 
have been evolutionarily conserved in vertebrates (Bentwich et al., 2005). Additional 
non-conserved miRNAs have also been characterized in primates, and humans are 
reported to contain about 800-1000 miRNAs (Bentwich et al., 2005; Zamore and Haley, 
2005). Little is known regarding how miRNA expression is regulated in mammalian 
cells. Primary miRNA transcripts are generated by polymerases II and III and they are 
usually capped and polyadenylated (Borchert et al., 2006; Kim and Nam, 2006). Some 
miRNAs are clustered and transcribed as multicistronic primary transcripts, but many 
others are not clustered and are transcribed independently (Ambros, 2004; He and 
Hannon, 2004; Landgraf et al., 2007). These miRNAs can downregulate various gene 
products by translational repression when partially complementary sequences are 
present in the 3’ untranslated regions (3’-UTR) of the target mRNAs or by directing 
mRNA degradation. Using these post-transcriptional control mechanisms, mammalian 
miRNAs appear to target a diversity of cellular functions including cell proliferation 
and differentiation (He and Hannon, 2004).  
 In the last few years, it has become evident that miRNA expression is 
deregulated in human cancer resulting in specific oncogenic events reviewed in (Calin 
and Croce, 2006; Esquela-Kerscher and Slack, 2006). Specific over- or underexpression 
has been shown to correlate with particular tumor types (Lu et al., 2005; Volinia et al., 
2006). These changes in expression might modulate known oncogenes or tumor 
suppressors. For example, let-7, a microRNA that inhibits RAS expression, is 
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downregulated in lung cancer leading to increased RAS protein levels (Johnson et al., 
2005). On the other hand, miR-17-5p and miR-20a modulate the balance between cell 
death and proliferation in response to the c-Myc oncogene (O'Donnell et al., 2005). In 
some cases, it has been demonstrated that miRNAs are inactivated by specific genetic or 
epigenetic alterations. Thus, miR-15a and miR-16-1 are inactivated by deletions or 
specific translocations in their chromosomal regions (Calin et al., 2002). In fact, 
microRNAs exhibit a high frequency of DNA copy changes that correlate with altered 
levels of expression in various human malignancies (Zhang et al., 2006). Other 
microRNAs are inactivated by epigenetic mechanisms and their re-expression by 
epigenetic drugs can lead to down-regulation of target oncogenes (Brueckner et al., 
2007; Fazi et al., 2007; Lujambio et al., 2007; Saito et al., 2006). Altered expression of 
miRNAs, moreover, can predict clinical outcome (Calin et al., 2005; Takamizawa et al., 
2004; Yanaihara et al., 2006), suggesting that miRNAs play an important role in human 
cancer. 
 In this study, we have identified a region of mouse chromosome 12 (F2 region, 
conserved in human chromosome 14q32) that is frequently lost in T-cell malignancies. 
This chromosomal region is especially rich in microRNAs since it contains several 
clusters of microRNAs and expresses 52 mature microRNAs (about 12% of the 
mammalian miRNA genome: miRBase v 10.0). We have narrowed down the fragile site 
to a region of about 7 Mb that contains 51 out of these 52 miRNAs. After miRNA 
expression profiling, we have detected significant silencing of one of these miRNAs, 
miR-203. Since affected tumors usually lose only one copy of this DNA region, we 
have investigated whether miR-203 expression is also downregulated by epigenetic 
mechanisms. We demonstrate here that miR-203 is silenced by the loss of one allele and 
promoter CpG hypermethylation in the remaining DNA copy. We have further 
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identified ABL1 as one of the targets of miR-203, indicating that both genetic and 
epigenetic mechanisms participate in transcriptional silencing of miR-203 leading to 
upregulation of the ABL1 and BCR-ABL1 oncogenes in various murine and human 
hematopoietic malignancies. Restoration of miR-203 by exogenous transfection or 
epigenetic drugs results in ABL1 and BCR-ABL1 downregulation (similar to that 
elicited with RNA interference) and decreased proliferation of tumor cells. This 
antiproliferative effect is partially rescued by overexpression of BCR-ABL1 and fully 
rescued by a BCR-ABL1 cDNA without the endogenous 3’-UTR suggesting that ABL1 
is a crucial target of the tumor suppressor activity of miR-203. 
 
 
Results 
A chromosomal region enriched in microRNAs is frequently lost in irradiated T-
cell lymphomas 
In a search for genomic alterations throughout the tumor genome we performed 
comparative genome hybridization (CGH) of 12 γ-radiation-induced lymphomas versus 
wild-type tissues from C57BL/6J mice. We identified consistent DNA losses in the 
telomeric region of chromosome 12 (about 50% of samples; N=12). CGH analysis of 
this fragment (Figure 1A) did not provide resolution enough to analyze putative 
candidate tumor suppressor genes. We therefore further refined this region using 
specific single-strand conformation polymorphism (SSCP) analysis in 44 additional 
tumor samples using F1 mice generated from crosses between pure C57BL/6J and RF/J 
inbred mice. These studies demonstrated that the DNA fragment most frequently lost in 
these tumors corresponds to the chromosome region between markers D12Mit132 and 
D12Mit18 (chromosome 12 positions 107.4 to 113.7 Mb) (Figure 1B). This region 
 7
contains about 80 protein-coding genes, including Bcl11b, a potential tumor suppressor 
candidate for this region (Wakabayashi et al., 2003). Interestingly, in addition to these 
genes, this chromosomal region also contains 52 microRNAs (Figure 1C), accounting 
for about 12% of the known microRNAs in the mouse genome (Sanger miRBase 
repository, Release 10.0; August 2007) (Griffiths-Jones et al., 2006). These microRNAs 
include several clusters located at the callipyge locus, a chromosomal region known to 
be regulated by genomic imprinting (Davis et al., 2005) and other non-clustered 
microRNAs.  
 
Genetic and epigenetic alteration of mouse and human miR-203 
To analyze whether some of these miRNAs were silenced in T-cell malignancies, we 
performed expression profiling using miRNA microarrays (Figure 2). High-stringency 
analysis of these tumors indicated that only one of these miRNAs, miR-203 was 
significantly silenced in murine T-cell lymphomas (FDR < 0.001; Δ = 1.4; Figure 2B).  
Since these murine T-cell lymphomas lost expression of miR-203, despite 
maintaining a normal allele, we analyzed whether this miRNA could be silenced by 
epigenetic mechanisms. miR-203 presents a clear CpG island in its upstream 
chromosomal region flanking the transcriptional start site (TSS) similar to that present 
in many tumor suppressor genes (Figure 3). As a control, we used miR-345 since it also 
presents a clear CpG island in its upstream chromosomal region and both are located in 
the chr. 12 region deleted in these T-cell malignancies. After bisulfite conversion of 
genomic DNA from these samples, we could not detect any methylation at the miR-345 
CpG island, either in normal lymphocytes or tumor samples (Supplementary Figure 
1A). Similarly to miR-345, miR-203 was not methylated in normal lymphocytes. 
However, it was significantly methylated in 7 out of 8 murine T-cell lymphoma tumor 
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samples (Figure 3). Detailed analysis by bisulfite sequencing indicated that most of the 
CpG dinucleotides in this CpG island were methylated in some tumors but not in 
normal lymphocytes (Figure 3C).   
The chromosome 12 region identified in mouse T-cell lymphomas is synthenic 
to a telomeric region in human chromosome 14. Interestingly, all microRNA clusters 
and genes located at this region in the mouse are conserved in the human genome. In 
fact, both the miR-203 pre-miR and its putative TSS are highly conserved between 
human and mouse genomes (Figure 3B). To test whether this epigenetic silencing of 
miR-203 was also present in human tumors, we analyzed four human T-cell tumor cell 
lines (KARPAS-45, PEER, JURKAT and MOLT-4) and three additional primary peripheral 
T-cell leukemias by methylation-specific PCR (MS-PCR) analysis. In all these human 
samples, miR-203 was dramatically hypermethylated as detected by MS-PCR 
(Supplementary Figure 1B) and bisulfite sequencing (Figure 3D), whereas this sequence 
was not methylated in human normal T-lymphocytes. 
 
miR-203 directly regulates ABL1 expression 
Computational prediction of both human and mouse miRNA targets [TARGETSCANS and 
PICTAR (Rajewsky, 2006)] suggests that miR-203 can modulate more than 300 genes. 
To further select a functional miR-203 target, we performed massive mRNA expression 
analysis of mouse T-cell lymphomas with silenced miR-203 to identify possible targets 
upregulated in these tumors. Twenty-two of the putative miR-203 targets are 
significantly overexpressed in these T-cell lymphomas (Figure 4A), including Abl1, the 
murine homolog of ABL1, a known oncogene in hematopoietic malignancies (Ren, 
2005). In fact, Abl1 is overexpressed in these T-cell tumors as detected by protein 
analysis, indicating a correlation between Abl1 over-expression (Figure 4B) and loss of 
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miR-203 in these primary tumors (Figure 4B and Supplementary Figure 2). Both the 
murine and human 3’-UTR of ABL1 genes contain miR-203 target sequences with a 
computed free energy of –26.8 kcal/mol and –21.0 kcal/mol, respectively (Figure 4C). 
This target site is well conserved in other vertebrates (Supplementary Figure 3) 
suggesting that miR-203 may control ABL1 levels in a variety of organisms.  
To experimentally validate that miR-203 can target ABL1, we analyzed ABL1 
protein levels in human T-cell tumor cell lines after re-expression of miR-203. KARPAS-
45 or PEER cells ―both containing a methylated miR-203 promoter (see Figure 3D)―, 
were infected with retroviral vectors expressing GFP or co-expressing GFP and miR-
203. GFP-positive cells were isolated by cytometry and analyzed by immunoblot. As 
indicated in Figure 5, re-expression of miR-203 results in decelerated growth (doubling 
time of about 56 h in both cell lines), compared to control cells infected with the empty 
retrovirus (doubling time of about 24 h in both control cultures). This antiproliferative 
response is accompanied by a dramatic reduction (of about 70%) in ABL1 levels in 
these tumor lymphocytes in both KARPAS-45 and PEER and cell lines (Figure 5 and 
Supplementary Figure 4). Interestingly, the antiproliferative effect elicited by miR-203 
is similar to that observed after expressing a pool of four different small-hairpin 
interfering RNAs specific for the human ABL1 gene (Figure 5B and Supplementary 
Figure 4A), suggesting a specific requirement for ABL1 in these T-cell lymphomas. 
Next, we subcloned the ABL1 3’UTR downstream of a luciferase reporter vector 
to analyze whether miR-203 directly targets ABL1 as predicted from the alignment. In 
293 cells, miR-203, but not GFP, is able to reduce luciferase activity in this construct by 
30% (Figure 5C) indicating that this microRNA may directly target the ABL1 3’-UTR. 
This reduction is abolished by a 3’-UTR that contains specific point mutations in the 
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seed region of the miR-203 target sequence (Figure 5C), indicating that miR-203 can 
directly influence ABL1 protein levels through specific binding to its 3’-UTR. 
 
Specific methylation of miR-203 in Philadelphia-positive human leukemias 
To further investigate the relevance of miR-203 in the oncogenic activity of ABL1, we 
next analyzed the epigenetic silencing of miR-203 in human tumors carrying a 
Philadelphia (Ph) chromosome. This alteration produces a BCR-ABL1 fusion protein 
that drives tumor development in several malignancies including some B-cell acute 
lymphoblastic leukemias (B-cell ALL) in children and chronic myelogenous leukemias 
(CML). As shown in Figure 6 (and Supplementary Figure 5) the upstream region of the 
human miR-203 is heavily hypermethylated in most Ph-positive tumors, including B-
cell ALLs and both primary CMLs and cultured CML cell lines.  This methylation 
correlates with decrease expression in these Philadelphia-positive tumors 
(Supplementary Figure 2B). Interestingly, the miR-203 promoter region is not 
methylated in other hematopoietic tumors that do not carry ABL1 alterations. Thus, 
miR-203 is not significantly methylated in acute myelogenous leukemias (AMLs) or 
chronic myeloproliferative diseases (CMPDs) that do not express ABL1 fusion proteins 
(Figure 6 and Supplementary Figure 5). These results suggest a specific pressure to 
down-regulate miR-203 in Philadelphia-positive tumors (CMLs and some B-cell ALL) 
or tumors that overexpress ABL1 (such as T-cell lymphomas). 
 
Modulation of ABL1 and BCR-ABL1 expression by miR-203 and epigenetic drugs 
Re-introduction of miR-203 in the CML cell lines K562 and KCL-22 results in 
restoration of miR-203 expression and concomitant reduction of ABL1 protein levels 
(Figure 7 and Supplementary Figure 4B). These cell lines also express the BCR-ABL1 
 11
fusion protein resulting from the Philadelphia chromosome translocation. Importantly, 
re-expression of miR-203 also results in reduced BCR-ABL1 levels (Figure 7A and 
Supplementary Figure 4B), likely due to the presence of the ABL1 3’-UTR in the BCR-
ABL1 fusion transcript. This reduction in ABL1 and BCR-ABL1 protein levels is 
accompanied by a dramatic decrease in the proliferation rate in these CML cells (Figure 
7B). As in T-cells, downregulation of ABL1 and BCR-ABL1 by specific shRNAs 
results in a similar proliferation arrest. This arrest is accompanied by apoptotic cell 
death induced by both miR-203 and, more dramatically, ABL1 shRNAs (Figure 7C). To 
directly analyze whether the translocated ABL1 is a critical target of miR-203 in this 
antiproliferative activity in CML cells, we exogenously expressed the p210 BCR-ABL1 
fusion protein containing its endogenous 3’-UTR downstream the cDNA. This protein 
has little effect on K562 or KCL-22 cells (about 10% increase in cell numbers three 
days after transfection; data not shown), but results in a significant rescue from miR-
203-induced cell arrest (Figure 7D). As this exogenous BCR-ABL1-3’-UTR construct 
contains the miR-203 target site, it probably competes with the endogenous BCR-ABL1 
transcript reducing the titter of miR-203. We also tested two additional BCR-ABL1 
translocation variants (p210 and p190) devoid of their 3’UTR, and therefore not 
containing miR-203 target sites. As shown in Figure 7D, expression of these miR-203-
resistant BCR-ABL1 cDNAs in K562 and KCL-22 tumor cells fully overcomes the 
antiproliferative effect of miR-203 resulting in a significant increase in cell 
proliferation.  
 Finally, since promoter methylation can be reversed using specific epigenetic 
drugs, we treated two T-cell leukemias, KARPAS-45 and PEER, and two Ph-positive 
CML cell lines, K562 and KCL-22, with 5’-azacytidine (Aza), 4-phenylbutyrate (PBA) 
or a mixture of both drugs. Whereas single treatments with Aza alone or PBA alone 
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have a minor effect on miR-203 demethylation in all these cell lines (Supplementary 
Figures 6 and 7), the combined treatment results in a partial but efficient demethylation 
of the miR-203 upstream region both in T-cell leukemias (Supplementary Figure 6) and 
CML cell lines (Figure 8). This combined treatment restores miR-203 expression and 
re-expression of this miRNA strongly correlates with a significant reduction in both 
ABL1 and BCR-ABL1 protein levels (Figure 8 and Supplementary Figures 6 and 7). 
These results suggest that epigenetic drugs, in addition to re-express other methylated 
cDNAs, can result in oncogene downregulation mediated by the chemical restoration of 
miRNA function. 
 
Discussion 
It has been recently reported that miRNA loci are frequently located at fragile sites and 
suffer frequent genomic alterations in human cancer (Calin et al., 2004; Zhang et al., 
2006). As we have described here, loss of heterozygosity is relatively frequent in a 7-
Mb region surrounding the callipyge locus in γ-radiation induced T-cell lymphomas, a 
model of neoplasia that resembles human peripheral T-cell lymphomas (Melendez et al., 
2003). This region, located at chromosome 12 in mice and chromosome 14 in humans, 
contains some imprinted genes involved in the regulation of muscle and fat biology 
(Georges et al., 2003). Apart from these genes, this region contains a surprisingly high 
density of miRNAs and about 12% of the known mammalian miRNome is located at 
this position. Most of these miRNAs are clustered into several transcripts, including six 
miRNAs at the antiPeg11 transcript that participate in the trans regulation of the 
Rtl1/Peg11 gene (Davis et al., 2005). About 30 additional miRNAs are expressed in 
about four different transcripts downstream of the callipyge region, although all of these 
transcripts seem to be maternally expressed and controlled by genomic imprinting (Seitz 
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et al., 2004; Seitz et al., 2003). In fact, normal lymphocytes display diverse methylation 
of a CpG island flanking miR-134, likely as a consequence of the genomic imprinting at 
this locus (MJB and MM, unpublished observations). The presence of this large number 
of miRNAs might confer specific susceptibility to chromosomal breaks and large 
miRNA clusters have been previously suggested to produce fragile sites (Calin et al., 
2004). 
 Among the miRNAs encoded in this area, miR-203 (located about 2 Mb 
downstream of the callipyge region) is the only sequence significantly downregulated in 
these T-cell lymphomas. Recent results have indicated that some other microRNAs in 
this area, such as miR-127, are also deregulated in human tumors by promoter 
methylation (Saito et al., 2006). We have demonstrated in this report that specific 
deletions in this region are selected in T-cell tumor development where miR-203 is 
specifically silenced by epigenetics means. Thus, genetic and epigenetic mechanisms 
coordinately inactivate some specific miRNAs such as miR-203 in these neoplasias. 
 Expression of miR-203 seems to be restricted to specific cell types. Thus, miR-
203 is significantly expressed in the epidermis but not in the hair follicles of the skin 
(Yi et al., 2006). In these cells, conditional deletion of the miRNA processing enzyme 
Dicer results in decreased expression of miR-203 along with other miRNAs and 
provokes developmental perturbations in epidermal organization (Yi et al., 2006). miR-
203 is not expressed either in primary fibroblasts or in many other established cell lines 
(MJB and MM, unpublished observations). Moreover, inhibition of miR-203 expression 
induces increased cell proliferation (Cheng et al., 2005), suggesting an antiproliferative 
function for this miRNA.  
Bioinformatics analyses predict that conserved vertebrate miRNAs target more 
than 100-400 regulatory genes. Among the putative targets of miR-203 we have 
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validated ABL1 as a relevant target, at least in hematopoietic cells. ABL1 is a non-
receptor tyrosine kinase that is expressed in most tissues and participates in the 
transduction of signals from cell-surface growth factor and adhesion receptors to 
regulate cytoskeleton structure (Ren, 2005). ABL1 is involved in the development of 
the hematopoietic system and its overexpression is associated with the development of 
diverse hematopoietic malignancies (Lin et al., 2006; Ren, 2005). ABL1 plays an 
important role in T-cell signalling (Zipfel et al., 2004), mediates resistance to apoptosis 
in T-lymphocytes (Fuchs et al., 1995), and it is overexpressed in T-cell tumors, in some 
cases as a result of chromosomal translocations with amplification as reported in the 
NUP214-ABL1 fusion (Graux et al., 2004; Graux et al., 2006). As reported in this 
article, RNAi-mediated downregulation of ABL1 in T-cell leukemia cells reduces 
proliferation of these tumor cultures (Figure 5), suggesting putative therapeutic uses of 
ABL1 inhibitors in these malignancies. 
 The BCR-ABL1 fusion is a landmark of CML and it is also present in a 
percentage of B-cell ALL with poor prognosis. All of these diseases, but not other 
Philadelphia-negative leukemias, are accompanied of promoter methylation and 
decreased expression of miR-203 (Figures 6 and Supplementary Information) 
suggesting a proliferative advantage in silencing miR-203 in these tumor cells. It is also 
interesting to note that the 14q32 region of human chromosome 14 where this miRNA 
resides is frequently lost in lymphoid blast crisis of CML patients (Dastugue et al., 
1986; Sercan et al., 2000). It is therefore tempting to speculate that acute transformation 
and progression of the disease may be accompanied by inactivation of tumor suppressor 
genes in this region, including miRNAs such as miR-203. 
The recent success of some ABL1-targeted small molecule kinase inhibitors in 
CML and other diseases (Baselga, 2006; Ren, 2005) has suggested that inhibition of 
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ABL is critical for tumor treatment in these patients. In fact, CML patients with 
decreased levels of BCR-ABL1 transcripts have a significantly lower risk of disease 
progression (Druker et al., 2006). The fact that some miRNAs such as miR-203 can 
modulate ABL1 levels suggest that restoration of the expression of these miRNA can be 
beneficial to ALL or CML patients carrying the NUP214-ABL1 or BCR-ABL1 fusions. 
In addition, T-cell lymphoma/leukemia patients with high ABL1 protein levels could 
also benefit from these treatments. Kinase inhibitors such as imatinib (Gleevec) do not 
completely eradicate ABL1- or BCR-ABL1-expressing cells from the body, and 
resistance in some cases emerges as a consequence of point mutations that render 
resistant isoforms of ABL1 or by amplification and overexpression of the BCR-ABL 
fusion (Shannon, 2002). Since the oncogenic transcripts in these translocations contain 
the target site for miR-203, our results suggest that restoration of miRNA function 
might provide some beneficial effects for imatinib-resistant patients. Our data are also 
in agreement with the finding that epigenetic drugs such as decitabine display some 
therapeutic beneficts even in patients resistant to Imatinib (Issa et al., 2005). 
 
 
Experimental procedures 
Mouse colony and induction of tumors. C57BL/6J and RF/J F1 hybrid mice and pure 
C57BL/6J animals were maintained in our animal facilities following the appropriate 
ethical recommendations from our institutions. For tumor induction, 4-week-old mice of 
both sexes were exposed to four weekly doses of 1.75 Gy/dose of ionizing gamma 
radiation (Guerrero et al., 1984). Treated mice were observed daily until moribund, then 
sacrificed and autopsied. Normal and tumoral tissues were processed for histological 
analysis (paraffin embedding and haematoxylin and eosin staining) following standard 
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protocols. DNA, RNA and proteins were isolated from these samples as described 
below. 
 
Comparative Genome Hybridization. For DNA preparation thymic lymphomas and 
normal tissues were cut, minced in small pieces and placed in a microfuge tube 
containing 0.5 ml lysis buffer (20 mM Tris-HCL pH 8.0, 25mM EDTA, 0.5% SDS, 
0.1M NaCl). Proteinase K was added at a final concentration of 100 mg/ml and 
incubated at 55ºC overnight. The lysate was extracted twice with an equal volume of 
phenol:chloroform:isoamyl alcohol (25:24:1, v/v) (Gibco- BRL). DNA was precipitated 
by addition of an equal volume of isopropanol and dissolved in TE buffer (10mM Tris-
HCl, pH 8.0 and 1mM EDTA).  
About 3000 mouse BAC clones with an average spacing of 1 Mb across mouse 
chromosomes 1 to 19 and the X chromosome (Chung et al., 2004) were printed on 
hydrophobic glass slide surfaces using an Omni Grid 100 array printer (BioRobotics). 
The average spacing between the linear map positions of this 3K collection of BAC 
clones (calculated as the distance between the midpoint positions of two consecutive 
BACs) is about 0.9 Mb (Chung et al., 2004). For comparative genome hybridization on 
these BAC microarrays, 1 μg of tumor or normal DNA was first amplified and labelled 
with aminoallyl-dUTP (Sigma, St Louis, USA) using the Bioprime random priming kit 
(Gibco) and then further labelled with Cy3 or Cy5 monoreactive NHS esters 
(Amersham, Piscataway, NJ, USA). DNA samples from six non-treated C57BL/6J mice 
were pooled and used as a normal control. Tumor samples from male animals were 
hybridized to female pools and vice-versa to have an internal control on DNA gains and 
losses in chromosomes X and Y. In all, 1 μg of labelled tumor DNA and an equal 
amount of control DNA labelled differentially were mixed with 200 μg mouse Cot I 
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DNA (Gibco), dissolved in a formamide-based hybridization buffer containing 50% 
formamide, 2X SSC, 2% SDS and 10% dextran sulfate, heat denatured and annealed at 
37ºC to block repeats and then hybridized to BAC arrays. Hybridization was carried out 
in a shaker incubator at 37ºC for 16–20 h. Arrays were washed in 2X SSC, 0.1% SDS at 
45ºC for 60 min and immediately scanned after rinsing with deionized water. Array 
images were quantified using DNA Microarray Scanner G2565BA (Agilent). 
 
Loss of heterozygosity (LOH) analysis. LOH analysis was carried out by comparing 
electrophoresis patterns of tumor and control DNA. The following chromosome 12 
markers were used according to sequences reported in Mouse Genome Database:  
D12Mit64 (position 45.6 Mb), D12Mit4 (79.9 Mb), D12Mit239 (89.0 Mb), D12Mit132 
(107.4 Mb), D12Mit122 (107.6 Mb), D12Mit53 (107.9 Mb), D12Mit123 (109.3 Mb), 
D12Mit18 (113.7 Mb), and D12Mit144 (119.5 Mb; all positions refer to ENSEMBL 
database v. 39; Jun. 2006). In addition, a specific polymorphism in the Bcl11b gene was 
used at position 108.4 Mb as well as two different SNPs in this region (rs3700933 and 
rs3683037). The specific sequences used are available from the authors per request. 
PCR products were separated on a 3% agarose, 10% polyacrylamide gel for Single-
Strand Conformation Polymorphism (SSCP) analysis. 
 
MicroRNA and cDNA expression analysis. MicroRNA expression profiles were 
performed essentially as described previously (Liu et al., 2004). Briefly, tumor RNA 
was isolated using Trizol (Invitrogen) and 5 μg of RNA were used for hybridization. 
MicroRNA microarrays have been described previously (Volinia et al., 2006). These 
microarrays were hybridized in 6x SSPE (0.9 M NaCl/60 mM NaH2PO4·H2O/8 mM 
EDTA, pH 7.4)/30% formamide at 25°C for 18 h, washed in 0.75x TNT 
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(Tris·HCl/NaCl/Tween 20) at 37°C for 40 min, and processed by using a method of 
direct detection of the biotin-containing transcripts by streptavidin-Alexa Fluor 647 
conjugate. Processed slides were scanned using a microarray scanner, with the laser set 
to 635 nm, at fixed PMT setting, and a scan resolution of 10 mm. The SAM (Statistical 
Analysis of Microarray) tool included in the TM4 package 
(http://www.tm4.org/mev.html) was used to analyze the statistical significance of 
microRNA expression data.  
cDNA microarray experiments were performed using the CNIO RatonChip 23K 
(v3). This chip contains both the NIA15K and the 7.4K clone sets from the National 
Institute on Aging http://lgsun.grc.nia.nih.gov/cDNA/cDNA.html, plus 800 additional 
clones specifically associated to cancer, angiogenesis, apoptosis, signal transduction and 
stress processes obtained either from the Fantom1 collection (RIKEN) or the 
I.M.A.G.E. Consortium (Research Genetics, Huntsville, AL). About 3,000 clones are 
duplicated to reach a total of 27,648 spots, which included 166 spots containing non-
murine DNA as negative controls. Total RNA was extracted by combination of Trizol 
reagent (Invitrogen) and purification using the RNeasy Protect kit (Qiagen, Hilden). The 
quality of the RNA was evaluated using the BioAnalyzer system (Agilent). Twenty-five 
micrograms of the test or reference amplified RNAs were labeled with fluorescent Cy5 
and Cy3 (Amhersam, Sunnyvale), respectively using the SuperScript II RNase H 
Reverse Transcriptase KIT (Invitrogen,  USA). Hybridizations were performed at 55°C 
for 17 h using the SlideHyb Microarray Hybridization buffer (Ambion). In all 
microarray experiments, each sample was co-hybridized with a pool of amplified RNAs 
obtained from the Universal Mouse RNA (Stratagene, La Jolla, CA), used as a 
reference. After washing, the slides were scanned in an Agilent G2565BA scanner. 
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Images were then analyzed with GenePix 5.1 (Axon Instruments, Inc., Union City, CA) 
and the TM4 software. 
To validate expression of specific transcripts, total RNA from tumors and cell 
lines was isolated using Trizol (Invitrogen). Expression of miR-203 in mouse tumors 
was analyzed by Northern (NorthernMax, Ambion) or RNA protection  (mirVana, 
Ambion) assays using a miR-203 specific probe (see Supplementary Methods). 
6UsnRNA and miR-16+4 were used as controls in Northern hybridizations and RNA 
protection assays, respectively. The expression levels of individual microRNAs were 
quantified using the mirVana qRT-PCR miRNA detection kit following the 
manufacturer’s recommendations (Ambion). GAPDH served as normalization control. 
In addition, real-time quantitative amplification of miR-203 was performed in triplicate 
with the TaqMan MicroRNA assays kit (Applied Biosystems, Foster City, CA) 
according to the manufacturer instructions in an Applied Biosystems 7900HT Fast Real-
Time PCR apparatus. Amplification of RNU19 was used for normalization. The data 
analysis was done using the SDS (Sequence Detection Systems) 2.2.2 program (Applied 
Biosystems, Foster City, CA). 
 
DNA methylation analysis. The following human cell lines were obtained from the 
German Collection of Microorganisms and Cell Cultures (DSMZ): JURKAT, MOLT-4, 
KARPAS-45 and PEER (T-cell acute lymphoblastic leukemias; T-cell ALL), K562, 
KCL22 and EM-2 (chronic myelogenous leukemias; CMLs). Primary human T-cell 
ALLs (501T1, 3020201 and 220T), B-cell ALLs (06CG664, 06CG630 and 60344), 
CMLs (51226, 60514, 60515, 07CG1139, 07CG1187, 07CG1212, 07CG1257 and 
08B0061), acute myelogenous leukemias (AMLs: 07B1590, 07CG1192 and 
07CG1198 ) or chronic myeloproliferative diseases (CMPDs: 07CG1165, 
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07CG1155 and 07CG1197) were obtained from our repository or were kindly provided 
by J. Benitez, R. Villuendas or M.A. Piris (CNIO, Madrid). For methylation analysis, 
specific oligonucleotides were designed using the MethPrimer (Li and Dahiya, 2002) 
and Methyl Primer Express Software v1.0 (Applied Biosystems) to amplify methylated 
or unmethylated mouse or human microRNA promoters (Supplementary Table 1). 
Analysis of DNA methylation by MS-PCR or bisulfite sequencing was performed 
essentially as described previously (Saito et al., 2006). Briefly, genomic DNA (1 μg) 
was converted with sodium bisulfite as previously reported (Frommer et al., 1992). 
After amplification of the bisulfite-converted DNA, methylation levels were analyzed 
by sequencing of the bisulfite-modified promoter regions. 
For demethylation studies, cells were seeded at 4 x 105 cells per 10-cm dish 24 h 
prior to the treatment with 5 μM 5’-azacytidine (Aza; Sigma-Aldrich, St. Louis, MO), 3 
mM 4-phenylbutyrate (PBA; Sigma-Aldrich) or a combination of both drugs. Aza was 
given at the indicated doses continuously for 72 h. After 24 h of recovery, PBA was 
given at the indicated doses for 2 days in the combined protocol. 
 
DNA transfection and retroviral infection. Cultured cells were maintained at 
logarithmic growth in RPMI 1640 medium supplemented with 10% fetal bovine serum, 
2 mM L-glutamine, 1 mM sodium pyruvate, and 100 units/ml each of penicillin G and 
streptomycin. To analyze the effect of DNA de-methylation, cells were incubated for 
three days with 1-5 μM 5-aza-2’-deoxycytidine (5-aza; Sigma-Aldrich, St. Louis, MO) 
and/or 1-3 mM 4-phenylbutyric acid (PBA; Sigma-Aldrich). To re-express miR-203 in 
T-cells, we used a GFP-expressing MSCV-driven retroviral vector (a gift from S. 
González and M. Serrano; CNIO, Madrid) or a pBabe-puro-derivative vector containing 
a 400 bp genomic region around the hsa-miR-203 locus. These vectors were transfected 
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into 293T cells and the resulting viruses were incubated on KARPAS-45 and PEER cells. 
Three days after infection, GFP-positive cells were isolated by FACS (Becton-
Dickinson) and the selected cells were used for cell proliferation assays or 
immunoblotting on protein lysates. K562 and KCL-22 cells were transfected with 
pBabe-puromycin vectors using a nucleofector apparatus (Amaxa Biosystems, USA) 
following the manufacter’s recommendations. p-Babe-puromycin empty vector was 
used as a control. 24 hours after nucleofection cells were selected with 2 μg/ml of 
puromycin during 5 days. After selection cells were maintained in 1 μg/ml of 
puromycin and were used for cell proliferation assays. To rescue the antiproliferative 
effect of miR-203, cultured cells were cotrasfected with a EGFP-expressing MSCV-
driven retroviral vectors that express the BCR-ABL1 fusion proteins (p210 and p190) (a 
gift from Veronika Sexl, Medical University of Vienna; and Isidro Sánchez-García, 
CIC-Salamanca) and with a p-Babe-puromycin vector expressing miR-203 using 
nucleofector technology. Cells were maintained in puromycin selection during five days 
and then EGFP-positive cells isolated by FACS were used to determine the cell growth 
rate. For RNA interference, four different vectors that express small-hairpin RNAs 
against the human ABL1 were used (see Supplementary Methods and Supplementary 
Table 2). Apoptotic cell death was monitored using an Annexin V staining kit 
(Pharmingen BD Biosciences) following the manufacturer’s recommendations. 
 
Protein analysis and luciferase assays. Protein lysates were obtained from tissues or 
cells using RIPA Cell Lysis buffer (150 mM NaCl, 50 mM pH 8 Tris HCl, 0.5% 
Deoxychlorate sodium, 0.1% Sodium Dodecyl Sulphate and 1% Triton X-100, 1mM 
EDTA and 1mM EGTA) and the recommended amounts of Protease Inhibitor Cocktail, 
Phosphatase Inhibitor Cocktail 2 (Sigma, St. Louis, Mo) and Benzonase (Novagen, 
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Darmstadt, Germany). Samples were spun at 20,000 x g at 4ºC for 15 minutes, and the 
supernatant was stored at -80ºC or immediately quantified using a protein assay (Bio-
Rad). Seventy micrograms of protein lysates were loaded onto 8% polyacrylamide-SDS 
gels. Proteins were transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA) 
and probed with ABL1 antibodies (Calbiochem, Darmstadt, Germany). In addition, 
anti-α-tubulin antibody (Sigma, St. Louis, MO) was used as a loading control. After 
washing, blots were incubated with the appropriate secondary antibodies coupled to 
Alexa Fluor 680 and 800 nm (Invitrogen). Subsequently, the membrane was scanned 
using the Odyssey Infrared Imaging System (Li-Cor Biosciences).  
Luciferase constructs were made after amplification of the ABL1 3’-UTR and 
subcloning in a modified pGL3-Control vector (Promega). 293 or HeLa cells were 
transfected with 0.3 μg of firefly luciferase reporter vector containing the ABL1 3’-
UTR and 0.3 μg of the control vector containing Renilla luciferase pRL-CMV 
(Promega), using Effectene (Qiagen). Three micrograms of pMSCV-203 or the empty 
vector were used to analyze the effect of microRNA expression on luciferase signal. 
Luciferase assays were performed 48 h after transfection using the Dual Luciferase 
Reporter Assay System (Promega). Firefly luciferase was normalized to Renilla 
luciferase activity. 
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Figure Legends  
Figure 1. Chromosomal losses in mouse chromosome 12 by CGH and SSCP 
analysis. A) DNA copy losses detected by CGH in the murine tumors analyzed. The 
profile shows the area most frequently lost (cytobands F1 and F2) in these murine T-cell 
malignancies. B) Analysis of loss of heterozygosity by SSCP. The different markers 
used through the complete chromosome 12 are shown as vertical flags. DNA losses in 
cytobands D3 to F2 are shown by the intense colored boxes whereas less intense boxes 
indicate blind regions between the closer markers in their boundaries. C) The precise 
location of microRNAs located at the deleted region (107-114 Mb) is indicated by 
vertical lines. The “callipyge” clusters contain 44 additional microRNAs whose names 
have been omitted for clarity. 
 
Figure 2. Microarray analysis of chromosome 12 microRNA expression. A) Heat 
map showing the expression of miRNAs located at the deleted region in mouse 
chromosome 12 (between position 107 Mb and 114 Mb). B) Significance analysis of 
microarrays in these samples point to miR-203 as the only miRNA significantly 
downregulated (FDR < 0.0001) in tumor versus normal samples. 
 
Figure 3. DNA methylation analysis of miR-203 in mouse and human T-cell 
lymphomas and leukemias. A) Methylation-specific (MS-PCR) analysis of the miR-
203 upstream region in mouse chromosome 12. The percentage of C+G nucleotides 
(CG%) and the density of CpG dinucleotides are shown for a region spanning 4 kbp 
upstream of miR-203. Specific primers for this CpG island were designed (convergent 
arrows) and used to amplify these DNA fragments in normal and tumor samples. A MS-
PCR protocol was followed to specifically amplify unmethylated (U) or methylated (M) 
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DNA. Methylation of miR-203 upstream regions is patent in most tumor samples 
(asterisks) but not in normal cells. T-CL, T-cell lymphomas; NL, lymphocytes from 
normal thymuses; IVD, DNA methylated in vitro. H2O indicates amplification were 
H2O was used instead of lymphocyte DNA. B) VISTA plot showing the homology 
between the mouse and human region upstream miR-203. The two regions with higher 
homology correspond to the position of miR-203 and the transcriptional start site (TSS) 
as identified by computer analysis (Saini et al., 2007) and paired-end ditag identification 
(Ng et al., 2005). Pink areas in VISTA plot indicate the CpG island. The density of 
individual CpG dinucleotides is also shown in red. C) Bisulfite sequencing of the miR-
203 upstream region in mouse T-cell lymphomas (T-CL) and normal lymphocytes 
(NL). No CpG dinucleotides are methylated in control samples whereas some tumors 
such as 16CG63 and NRH5-2 are heavily methylated. D) Similar analysis in human T-
cell leukemia (T-CL) cell lines or primary tumors. Non-methylated CpG dinucleotides 
are shown by an empty circle whereas methyl-CpG is shown by filled circles. All CpG 
dinucleotides in a region of about 350 bp upstream of miR-203 are shown. Three 
representative tumor samples are shown for each group and three independent clones 
were sequenced per sample. 
 
Figure 4. Correlation between miR-203 inactivation and Abl1 overexpression in T-
cell lymphomas. A) Analysis of the expression of putative miR-203 targets by cDNA 
microarray analysis. Only 22 miR-203 predicted targets, including Abl1, are 
significantly upregulated in these T-cell lymphomas as indicated by the significance 
analysis of microarrays (FDR < 0.001). B) Correlation between the downregulation of 
miR-203 and upregulation of Abl1 in these tumors. miR-203 expression was detected 
by Northern blot using 6UsnRNA as a control. Abl1 expression was monitored at the 
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protein level as detected by immunoblotting. α-tubulin was used as a loading control. C 
indicates control (normal thymus) samples whereas T indicates T-cell lymphomas. 
These data were quantified and normalized with the corresponding controls 
(histograms). C) Predicted duplexes formed between miR-203 and the mouse and 
human 3’-untranslated regions (UTR) of ABL1. The seed region is highlighted in a grey 
box. The prediction was calculated using the PicTar algorithm (Krek et al., 2005).  
 
Figure 5. Direct downregulation of ABL1 by miR-203. A) ABL1 protein levels in 
KARPAS-45 cells expressing GFP (GFP) or GFP + miR-203 (203), indicating a 3-fold 
reduction of ABL1 levels in the presence of miR-203. α-tubulin was used as a loading 
control. ABL1 and α-tubulin signals were quantified and their ratio was normalized to 
that of non-infected cells (NT). miR-203 transcript levels were quantified by real-time 
quatitative PCR and normalized versus the expression levels in NT KARPAS-45 cells 
(relative value = 1). B) Growth rate of KARPAS-45 and PEER cells expressing miR-203 
(filled circles), a pool of shRNAs against ABL1 (grey circles) or the empty vector (open 
circles). C) Luciferase activity in DNA constructs carrying the wild-type ABL1 3’-UTR 
or mutated versions (mutated residues are underlined) downstream of the luciferase 
reporter. 293 cells were cotransfected with pG-ABL1 (carrying the luciferase-ABL1-
3’UTR quimera) and a plasmid expressing GFP or miR203. The reduction in luciferase 
activity induced by miR-203 expression is reversed after mutation of three specific 
residues in the seed region of the miR-203 target site. Luciferase activity was 
normalized for transfection levels as indicated in the experimental procedures. Data 
shown are representative of separate assays at two different luciferase/miRNA ratios as 
indicated. *, significant differences at p<0.001; **, no significant differences found. 
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Figure 6. Specific methylation of miR-203 in Philadelphia(Ph)-positive human 
leukemias. Methylation map of the human miR-203 upstream region in Philadelphia-
positive (Ph+) tumors, including chronic myelogenous leukemias (CML) and CML 
tumor cell lines, and B-cell acute lymphoblastic leukemias (B-cell ALL). Additional 
leukemias that do not contain rearranged ABL1 loci such as acute myeloid leukemias 
(AML) and other chronic myeloproliferative diseases (CMPD) are also shown. In these 
Philadelphia-negative (Ph-) tumors miR-203 is not significantly methylated. Three 
representative tumor samples are shown for each group and three independent clones 
were sequenced per tumor sample. Normal blood cells were used as a control (NBC). 
 
Figure 7. Restoration of miR-203 expression in Philadelphia(Ph)-positive tumor 
cells downregulates ABL1 and BCR-ABL1. A) K562 cells were transfected with GFP 
or miR-203 vectors. Over-expression of miR-203 results in decreased ABL1 and BCR-
ABL1 protein levels as detected by immunoblotting. miR-203 transcript levels were 
quantified by real-time quatitative PCR and normalized versus the expression levels in 
non-transfected K562 cells (relative value = 1). α-tubulin was used as a protein loading 
control. ABL1, BCR-ABL1 and α-tubulin signals were quantified and their ratios were 
normalized to BCR-ABL1 protein levels in GFP-expressing cells. B) Growth rate of 
K562 and KCL-22 cells expressing miR-203 (filled circles), a pool of four shRNAs 
against ABL1 (grey circles) or the empty vector (open circles). C) Apoptotic cell death 
after transfection with miR-203 or ABL1 shRNAs in K562 or KCL-22 cell lines. These 
vectors were co-transfected with a GFP expressing plasmid and apoptosis was 
monitored with Annexin V staining five days after transfection. D) K562 or KCL-22 
cells were transfected with an empty vector, a vector expressing miR-203, or a 
combination of vectors expressing miR-203 and the BCR-ABL1-3’-UTR construct or 
 35
miR-203 and the p210 or p190 forms of BCR-ABL1 that do not contain the endogenous 
3’UTR. The overexpression of BCR-ABL1-3’-UTR partially rescue the effect of miR-
203, whereas the exogenous expression of miR-203-resistant BCR-ABL1 cDNAs fully 
rescues miR-203-mediated cell proliferation arrest. Three days after transfection, the 
number of cells was scored and normalized to the original number of cells transfected 
(fold increase). 
 
Figure 8. Restoration of miR-203 expression and downregulation of BCR and 
BCR-ABL1 by epigenetic drugs. A) The CML cell lines K562 and KCL-22 were 
treated with the epigenetic drugs Aza + PBA resulting in significant demethylation of 
the miR-203 upstream region. Three independent clones were sequenced per treated cell 
line. B) Upregulation of miR-203 and concomitant downregulation of ABL1 and BCR-
ABL1 protein levels after 5-aza + PBA treatment in K562 and KCL-22 cells. miR-203 
transcript levels were quantified by real-time quatitative PCR and normalized versus the 
expression levels in non-treated K562 or KCL-22 cells (relative value in untreated cells 
= 1).  ABL1, BCR-ABL1 and α-tubulin signals were quantified and their ratios were 
normalized to BCR-ABL1 protein levels in non-treated cells. 
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Supplementary Methods 
 
Analysis of microRNA expression by Northern/RNA protection Assays. For Northern blot 
analysis, miR203 and 6UsnRNA antisense probes were 5´end labelled with mirVanaTM probe Kit 
from Ambion. miR203 antisense probe: 5´-CTAGTGGTCCTAAACATTTCAC-3´; 6UsnRNA 
antisense probe 5´-TGCTAATCTTCTCTGTATCG-3´. Northern blot analysis of small RNA 
molecules were performed following the protocol provided by Ambion using NorthernMax 
reagents. 
For the RNase protection assay, antisense RNA probes, miR203 and miR16+4, were 
prepared by in vitro transcription (mirVanaTM miRNA probe construction (Ambion Cat: 1550) using 
the following DNA sequence (5’-GTGAAATGTTTAGGACCACTAGCCTGTCTC-3’) as a template 
for miR-203. miR16+4 DNA template is provided by the mirVanaTM miRNA detection kit (Ambion). 
Hybridization of probes and sample RNAs, and the RNase digestion assay was permorfed 
following the manufacturer’s protocols. 
 
RNA interference against ABL1. Four different oligonucleotides were design for generating 
short hairpin RNAs for the ABL1 target sequences listed in Supplementary Table 2. These 
oligonucleotides were designed to cover the targeted sequence flanked by the H1/u6 promoter 
and a polyA as previously used in pRetroSuper vectors [Brummelkamp, T.R., Bernards, R. and 
Agami, R. (2002) A system for stable expression of short interfering RNAs in mammalian cells. 
Science 296, 550-553]. The H1/U6 promoter-target-pA fragment was subcloned in a pENTRY 
vector (Invitrogen) and then moved to a pBabe-puromycin retroviral backbone using the Clonase 
recombinase (Invitrogen) to generate four different shRNA-producing vectors against the human 
ABL1. The position of each target sequence is listed in Supplementary Table 2. 
 
Supplemental Text and Figures
Click here to download Supplemental Text and Figures: 080122 Supplementary Information.pdf
Bueno el al. Genetic and Epigentic Silencing of miR-203  Supplementary Information 
2 
 
 
Supplementary Figures 
 
 
 
 
Supplementary Figure 1. DNA methylation analysis of miR-345 and miR-203 in human T 
cell leukemia cell lines and T-cell primary tumors. A) Methylation-specific (MS-PCR) analysis 
of the miR-345 upstream region in mouse chromosome 12. The percentage of C+G nucleotides 
(CG%) and the density of CpG dinucleotides are shown for a region spanning 4 kbp upstream of 
miR-345. Specific primers for these CpG islands were designed (convergent arrows) and used to 
amplify these DNA fragments in normal and tumor samples. A MS-PCR protocol was followed to 
specifically amplify unmethylated (U) or methylated (M) DNA. Methylation is not detect  either in 
normal lymphocytes (NL) or tumor samples (T-CL).  IVD, DNA methylated in vitro was used as a 
methylation control. H2O indicates amplification were H2O was used instead of lymphocyte DNA. 
B) MS-PCR analysis of miR-203 in T-cell lymphomas and cell lines. Unmethylated (U) or 
methylated (M) DNA was specifically amplified. Methylation of miR-203 upstream region is 
present in both tumor samples and tumor cell lines. IVD corresponds to DNA methylated in vitro. 
H2O indicates amplification were H2O was used instead of DNA.  
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Supplementary Figure 2. Expression of miR-203 in murine and human tumors. The 
expression levels of miR-203 were quantified using real-time quantitative RT-PCR in mouse T-
cell lymphomas and human chronic myelogenous leukemias (CMLs) using normal thymus or 
purified white cells, respectively, as controls.  
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Supplementary Figure 3. The miR-203 recognition site in the 3’-UTR of ABL1 is highly 
conserved. Comparison of the 3’UTR of the ABL1 genes in four different species (human, 
mouse, chimpanzee and rat) where this 3’-UTR has been predicted (Ensembl; release 48, 
December 2007). The region complementary to the mir-203 is completely conserved in the four 
species. Asterisks indicate nucleotides that are complementary to the miR-203 sequence.  
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Supplementary Figure 4. Downregulation of ABL1 and BCR-ABL1 by miR-203 and specific 
ABL1 shRNAs. A) The T-cell lymphoma cell line PEER  was transfected with a vector expressing 
the GFP, miR-203 or a pool of four shRNAs for ABL1. ABL1 levels were quantified by Western 
blot whereas miR-203 levels were quantified by real-time RT-PCR. B) Similar analysis of the 
efficiency of miR-203 and ABL1 shRNA in downregulating ABL1 and BCR-ABL1 levels in two 
different CML cell lines, K562 and KCL-22.  
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Supplementary Figure 5. Methylation-specific (MS-PCR) analysis of the miR-203 upstream 
region in different types of Philadelphia-positive (Ph+) or negative (Ph–) leukemias. 
Unmethylated (U) or methylated (M) DNA was specifically amplified using the oligonucleotides 
listed in Supp. Table 1. Methylation of miR-203 upstream region is present in Ph+ primary tumors 
and cell lines. IVD, DNA methylated in vitro. IVD corresponds to DNA methylated in vitro. NBC, 
normal blood cells. H2O indicates amplification were H2O was used instead of DNA.  
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Supplementary Figure 6. Demethylation and re-expression of miR-203 by epigenetic drugs 
in T-cell leukemia cell lines. A) KARPAS-45 and Peer cells were treated with 5-aza, PBA or a 
combination of both. After bisulfite conversion, the miR-203 promoter area was sequenced. Only 
the combined treatment was partially effective in de-methylating this region. B) Re-expression of 
miR-203 and downregulation of ABL1 after these epigenetic treatments.  
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Supplementary Figure 7. Demethylation and re-expression of miR-203 by epigenetic drugs 
in chronic myelogenous leukemia (CML) cell lines. A) K562 and KCL-22 cells were treated 
with 5-aza, PBA or a combination of both (see also Figure 8 in the main text). After bisulfite 
conversion, the miR-203 promoter area was sequenced. Only the combined treatment (Figure 8) 
was partially effective in de-methylating this region whereas the single treatment had no 
significant effect B) Re-expression of miR-203 and downregulation of ABL1 after these epigenetic 
treatments in KCL-22 cells.  
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Supplementary Tables 
 
Supplementary Table 1. Oligonucleotides used for Methylation-specific PCR (MS-PCR) and 
bisulphate sequencing (BS) analysis of the miR-203 upstream region in mouse and human 
samples. F, forward; R, Reserse; U, design for Unmethylated DNA; M, designed for Methylated 
DNA. Additional oligonucleotides used for cloning and mutagenesis of the human ABL1 3’-UTR 
are also shown.  
 
Locus Primer ID Sequence (5’-3’) Application 
mmu-miR-203 mmu-mir-203.F2 TTTTTTGGCGAGTATTGTAAAG BS 
mmu-mir-203.R2 ACACAAAAATTCTACACAACCC BS 
mmu-mir-203.UF GGTTGGTGATTTAGGGTTATTTTT MS-PCR 
mmu-mir-203.UR CAACATACCTACACCTTTTATACATC MS-PCR 
mmu-mir-203.MF GTCGGTGATTTAGGGTTATTTTC MS-PCR 
mmu-mir-203.MR GACGTACCTACGCCTTTTATACGT MS-PCR 
hsa-miR-203 hsa-mir-203.F GAATTCGGGAGGTTAGGTG BS 
hsa-mir-203.R ACCCCCTACCCTACTACAACC BS 
hsa-mir-203.UF GGGTTGTGGAGGATTAGTT MS-PCR 
hsa-mir-203.UR AAACAACTAAACTCCAAACA MS-PCR 
hsa-mir-203.MF GGGTCGTGGAGGATTAGTC MS-PCR 
hsa-mir-203.MR AAACGACTAAACTCCGAACG MS-PCR 
mmu-miR-345 mmu-mir-345.UF TTTGTTATTTGGTTTTTGGGT MS-PCR 
mmu-mir-345.UR ACCTCACTTACCAATTAATTACA MS-PCR 
mmu-mir-345.MF GTTATTTGGTTTTCGGGC MS-PCR 
mmu-mir-345.MR TCGCTTACCGATTAATTACG MS-PCR 
3’ UTR human 
ABL1 
H-ABL1-3UTR-2F AAAAGAATTCTGAAAGGGCCCTTCC
CCTCCCCCACT 
Cloning 
H-ABL1-3UTR-WT-2R AAAAACTAGTGGCAGGGCTTTGAAA
TGCTTCAAGAAC 
Cloning  
 
H-ABL1-3UTR-MT-2R AAAAACTAGTGGCAGGGCTTTTATA
GGCTTCAAGAAC 
Mutagenesis 
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Supplementary Table 2. ABL1 target sequences for RNA interference (See Supplementary 
Methods). The shRNA ID includes the start nucleotide of the targeted sequence in the reference 
transcript for the human ABL1 gene. 
 
 
shRNA ID Gene Exon Targeted sequence Reference transcript 
Hs_ABL1.136 ABL1 2 GCCGCTCGTTGGAACTCCA 
NM_005157.3; 
ENST00000318560 
Hs_ABL1.263 ABL1 3 AGCTCCGGGTCTTAGGCTA 
NM_005157.3; 
ENST00000318560 
Hs_ABL1.1486 ABL1 9 ACAATGTTCCAGGAATCCA 
S NM_005157.3 
ENST00000318560 
Hs_ABL1.3369 ABL1 11 GGAAATCAGTGACATAGTG 
NM_005157.3 
ENST00000318560 
 
 
 
